Bradley DeNardo

Associate Professor

Brown University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Year:

2026

Year:

2025

Purpose: Comprehensive molecular profiling was used to define the genomic and immune landscapes of leiomyosarcomas (LMS) by anatomic subtypes, which have not been completely characterized. Experimental Design: A total of 1,115 LMS samples, categorized into uterine LMS (uLMS), retroperitoneal LMS, or other LMS (oLMS), underwent DNA/RNA sequencing (Caris Life Sciences). Genomic/transcriptomic profiles were compared across subtypes. Immune profiling was compared with melanoma ( n = 1,255), an immunogenic tumor. Insurance claims data were used to infer real-world outcomes with immune checkpoint inhibitors (ICI) in LMS. Results: uLMSs ( n = 701) were molecularly distinct from retroperitoneal LMSs ( n = 166) and oLMSs ( n = 248). RB1 mutations and MAP2K4 copy-number amplification were more common in non-uLMS. MED12 mutations were almost exclusive to uLMS. Traditional ICI response biomarkers (i.e., PD-L1) did not vary by anatomic site. Non-uLMS demonstrated upregulated immune-related gene sets, including IFN and inflammatory response pathways, and higher immune cell infiltration, especially CD8 + T cells and B cells (>2-fold increase, P n = 138), 29% of patients with LMS receiving ICI were treated >6 months, indicating potential clinical benefit. Conclusions: Comprehensive profiling suggested that uLMS represents a molecularly distinct disease from non-uLMS. Although traditional ICI response biomarkers were similar across anatomic subtypes, uLMSs were immune cold compared with non-uLMS. Signals for ICI responsiveness, such as high TIS and immune cell abundance, in some tumors suggest that further research into immunotherapies for LMS is warranted.

Year:

2025

Collaborators (9)

Don S. Dizon

Tufts Medical Center

UNITED STATES
View details

Holly Lindsay

Associate Professor

University of Colorado Health

UNITED STATES
View details

Margaret von Mehren

Professor

Fox Chase Cancer Center

UNITED STATES
View details

Jaime F. Modiano

Alvin & June Perlman Professor of Animal Oncology

University of Minnesota

UNITED STATES
View details

Vaia Florou

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Andreas Seeber

Medical University of Innsbruck

AUSTRIA
View details

Mohd Khushman

Professor

Washington University in St. Louis

UNITED STATES
View details

Jonathan C. Trent

University of Miami Miller School of Medicine

UNITED STATES
View details

Kimberly Stegmaier

Chair, Department of Pediatric Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details